Outcomes in COVID-19 GB0139 studies

0 0.5 1 1.5+ All studies -40% 1 41 Improvement, Studies, Patients Relative Risk Mortality -40% 1 41 RCTs -40% 1 41 Late -40% 1 41 GB0139 for COVID-19 c19early.org November 2025 FavorsGB0139 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DEFINE Gaughan (RCT) -40% 1.40 [0.36-5.49] death 4/20 3/21 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Late treatment -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk All studies -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk 1 GB0139 COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors GB0139 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DEFINE Gaughan (RCT) -40% 1.40 [0.36-5.49] 4/20 3/21 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Late treatment -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk All studies -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk 1 GB0139 COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Favors GB0139 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DEFINE Gaughan (RCT) -40% 1.40 [0.36-5.49] death 4/20 3/21 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Late treatment -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk All studies -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk 1 GB0139 COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors GB0139 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DEFINE Gaughan (RCT) -40% 1.40 [0.36-5.49] death 4/20 3/21 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Late treatment -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk All studies -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk 1 GB0139 COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors GB0139 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DEFINE Gaughan (RCT) -40% 1.40 [0.36-5.49] 4/20 3/21 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Late treatment -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk All studies -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk 1 GB0139 COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Favors GB0139 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DEFINE Gaughan (RCT) -40% 1.40 [0.36-5.49] death 4/20 3/21 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Late treatment -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk All studies -40% 1.40 [0.36-5.49] 4/20 3/21 40% higher risk 1 GB0139 COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors GB0139 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DEFINE Gaughan (RCT) -40% 1.40 [0.36-5.49] death 4/20 3/21 Improvement, RR [CI] Treatment Control GB0139 COVID-19 outcomes c19early.org November 2025 Favors GB0139 Favors control